Natus Medical EBIT

The latest EBIT for NTUS is $33M as of March 2022. That compares with $-9.3M in the prior-year period — up 454.7% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Natus Medical's historical trend and sector peers before judging valuation or financial health.

Over the past year, NTUS's EBIT moved from $-9.3M to $33M — a 454.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Natus Medical's operating scale or balance-sheet position.

Against Healthcare companies, NTUS currently prints $33M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Natus Medical's growth, margins, and balance sheet.

A EBIT figure of $33M for NTUS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting NTUS's EBIT ($33M), review year-over-year change from $-9.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.